Pharmacokinetics of antifungal agents in neonates and young infants

Current Medicinal Chemistry

Volumn 19, Issue 27, 2012, Pages 4621-4632

  Regazzi, M ^a   Billaud, E M ^b   Lefeuvre, S ^b   Stronati, M ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Antifungal drugs; Fungal infections; Infants; Neonates; Pharmacokinetics; Safety

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; PYRIMIDINE; TRIAZOLE DERIVATIVE; VORICONAZOLE; MACROLIDE; PYRIMIDINE DERIVATIVE;

ARTICLE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; EVIDENCE BASED MEDICINE; HUMAN; INFANT; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MYCOSIS; NEWBORN; NONHUMAN; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); HALF LIFE TIME; REVIEW;

ANTIFUNGAL AGENTS; DRUG MONITORING; ECHINOCANDINS; HALF-LIFE; HUMANS; INFANT; INFANT, NEWBORN; MACROLIDES; MYCOSES; PYRIMIDINES;

EID: 84875259798     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803306402     Document Type: Article

References (93)

1. Lehrnbecher, T.; Groll A.H. Invasive Fungal Infections in the Pediatric Population. Expert Rev. Anti Infect. Ther., 2011, 9(3), 275-278.
2. Hope, W.W. and Drusano, G.L. Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. European Society of Clinical Microbiology and Infectious Diseases, CMI, 2009,15, 602-612.
3. Blyth, C.C.; Palasanthiran, P.; O'Brien, T. Antifungal therapy in children with invasive fungal infections: a systematic review. Pediatrics, 2007, 119(4), 772-784.
4. Lass-Flörl, C. Fungal infections in pediatric patients: a review of antifungal therapy. Expert Rev. Anti Infect. Ther., 2010, 8(2), 127-135.
5. Steinbach, W. Antifungal agents in children. Pediatr. Clin. N. Am., 2005, 52:895-915.
6. Steinbach, W.J. Epidemiology of Invasive Fungal Infections in Neonates and Children. Clin Microbiol Infect., 2010, 16(9), 1321-1327
7. Dornbusch, H.J.; Manzoni, P.; Roilides, E.; Walsh, T.J.; Groll, A.H. Invasive fungal infections in children. Pediatr. Infect. Dis. J., 2009, 28(8), 734-737.
8. Groll, A.H.; Shah, P.M.; Mentzel, C.; Schneider, M.; Just-Nuebling, G.; Huebner, K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect., 1996, 33(1), 23-32.
9. Lehrnbecher, T.; Frank, C.; Engels, K.; Kriener, S., Groll, A.H., Schwabe D. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect., 2010, 61(3), 259-265.
10. Levy, O.; Martin, S.; Eichenwald, E. et al. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeabilityincreasing protein. Pediatrics, 1999, 104[6], 1327-1333.
11. Almirante, B.; Rodríguez, D. Antifungal agents in neonates: issues and recommendations. Paediatr Drugs, 2007, 9(5), 311-321.
12. Lass-Flörl, C. Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy. Expert Rev. Anti Infect. Ther., 2010 Feb, 8(2), 127-135.
13. Watt, K.; Benjamin Jr, D.K.; Cohen-Wolkowiez, M. Pharmacokinetics of antifungal agents in children. Early Human development, 2011, 87S, S61-S65.
14. Lutsar, I.; Metsvaht, T. Understanding pharmacokinetics/pharmacodynamics in managing neonatal sepsis. Curr. Opin. Infect. Dis., 2010 Jun, 23(3), 201-207.
15. Cakir M, Mutlu M, Aydin-Mungan S, Cansu A, Aslan Y, Erduran E. Neonatal hemochromatosis: a case report with unique presentation Turk J Pediatr. 2011 Jul-Aug;53(4), 455-9.
16. Lyman, C.A. and Walsh, T.J. Systemically Administered Antifungal Agents. A Review of Their Clinical Pharmacology and Therapeutic Applications. Drugs, 1992, 44(1), 9-35.
17. Benson, J.M. and Nahata, M.C. Clinical Use of Systemic Antifungal Agents. Clin. Pharm., 1988, 7(6), 424-438.
18. EMA/480197/2010. Revised priority list for studies into off-patent paediatric medicinal products. For the 5th Call 2011 of the 7th Framework Programme of the European Commission. Rev. 2010-update 17/11/2010
19. Gallis, H.A.; Drew, R.H. and Pickard, W.W.; Amphotericin B: 30 Years of Clinical Experience. Rev. Infect. Dis., 1990, 12(2), 308-329.
20. Benson, J.M. and Nahata, M.C. Pharmacokinetics of Amphotericin B in Children. Antimicrob. Agents Chemother., 1989, 33 (11), 1989-1993.
21. Anderson, R.P. and Clark D.A. Amphotericin B Toxicity Reduced by Administration in Fat Emulsion. Ann. Pharmacother., 1995, 29(5), 496-500.
22. Arsura, E.L.; Ismail, Y.; Freedman, S., et al. Amphotericin B-Induced Dilated Cardiomyopathy. Am J Med, 1994, 97(6), 560-562.
23. Benson, J.M. and Nahata, M.C. Pharmacokinetics of Amphotericin B in Children. Antimicrob. Agents Chemother., 1989, 33(11), 1989-1993.
24. Goodwin, S.D.; Cleary J.D.; Walawander, C.A.; et al. Pretreatment Regimens for Adverse Events Related to Infusion of Amphotericin B. Clin. Infec.t Dis., 1995, 20(4), 755-761.
25. Kintzel P.E. and Smith, G.H. Practical Guidelines for Preparing and Administering Amphotericin B. Am. J. Hosp. Pharm., 1992, 49(5), 1156-1164.
26. Koren, G.; Lau, A.; Klein, J., et al. Pharmacokinetics and Adverse Effects of Amphotericin B in Infants and Children. J. Pediatr., 1988, 113(3), 559-563.
27. Levy, M.; Domaratzki, J.; and Koren, G. Amphotericin-Induced Heart Rate Decrease in Children. Clin. Pediatr. [Phila], 1995, 34(7), 358-364.
28. Patel, R. Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine. Mayo Clin. Proc., 1998, 73(12), 1205-1225.
29. Slain, D. Lipid-Based Amphotericin B for the Treatment of Fungal Infections. Pharmacotherapy, 1999, 19(3), 306-323.
30. Wong-Beringer, A.; Beringer, P.M. and Rho, J.P. Focus on Amphotericin B Lipid Complex. Formulary, 1996, 13(3), 169-185.
31. Würthwein, G.; Groll, A.H.; Hempel G.; Adler-Shohet F.C.; Lieberman, J.M., Walsh, T.J. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob. Agents Chemother. 2005 Dec, 49(12), 5092-5098.
32. Kotwani, R.N.; Gokhale, P.C., Bodhe, P.V.; Kirodian, B.G., Kshirsagar, N.A.; Pandya, S.K. A comparative study of plasma concentrations of liposomal amphotericin B [L-AMP-LRC-1] in adults, children and neonates. Int J Pharm., 2002 May 15, 238(1-2), 11-15.
33. Tollemar, J; Klingspor, L; Ringdén, O. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children. Clin Microbiol Infect., 2001, 7 (Suppl 2), 68-79.
34. Baley, J.E.; Meyers, C.; Kliegman, R.M.; Jacobs, M.R.; Blumer, J.L. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr., 1990 May, 116(5), 791-797.
35. Starke, J.R., Mason Jr, E.O.; Kramer, W.G.; Kaplan, S.L. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis., 1987 Apr, 155(4), 766-774.
36. Cuzzolin, L.; Fanos, V.; Pinna, B.; di Marzio, M.; Perin, M.; Tramontozzi, P.; Tonetto, P.; Cataldi, L. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr Nephrol 2006, 21, 931-8
37. Ward, R. M.; Sattler F. R.; Dalton Jr, A. S. Assessment of Antifungal Therapy in an 800-Gram Infant with Candidal Arthritis and Osteomyelitis. Pediatrics, 1983 August 1, 72 (2), 234-238.
38. Frattarelli, D.A.; Reed, M.D.; Giacoia, G.P.; et al. Antifungals in systemic neonatal candidiasis. Drugs; 2004, 64, 949-968.
39. Soltani, M.; Tobin, C.M.; Bowker, K.E.; Sunderland, J.; MacGowan, A.P.; Lovering, A.M. Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents., 2006 Dec, 28(6), 574-577.
40. Pasqualotto, A.C.; Howard, S.J.; Moore C.B.; Denning, D.W. Flucytosine therapeutic monitoring: 15 years experience from the UK. J. Antimicrob. Chemother., 2007 Apr, 59(4), 791-793.
41. Cohen-Wolkowiez, M.; Moran, C.; DO, Benjamin Jr., D. K. and Brian Smith, P. Pediatric Antifungal Agents. Curr. Opin. Infect. Dis., 2009 Dec, 22(6), 553-558.
42. Novelli,V. and Holzel, H. Safety and Tolerability of Fluconazole in Children. Antimicrobial Agents and Chemotherapy, 1999 Aug, 43 (8), 1955-1960.
43. Groll, A.H. and Tragiannidis, A. Update on antifungal agents for paediatric patients. Clin. Microbiol. Infect. 2010, 16, 1343-1353.
44. Lee, J.W.; Seibel, N.L.; Amantea, M.; Whitcomb, P.; Pizzo P.A.; Walsh, T.J. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J. Pediatr., 1992, 120, 987-993.
45. Brammer, K.W.; Coates, P.E. Pharmacokinetics of fluconazole in pediatric patients. Eur. J. Clin. Microbiol. Infect. Dis. 1994 Apr,13(4), 325-329.
46. Saxén, H.; Hoppu, K., Pohjavuori, M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin. Pharmacol. Ther., 1993 Sep,54(3), 269-277.
47. Schwarze, R.; Penk, A.; Pittrow, L. Administration of fluconazole in children below 1 year of age. Mycoses., 1999 Apr,42(1-2), 3-16.
48. Wade, K.C.; Wu, D.; Kaufman, D.A.; Ward, R.M.; Benjamin, D.K. Jr.; Sullivan, J.E.; Ramey, N.; Jayaraman, B.; Hoppu, K.; Adamson, P.C.; Gastonguay, M.R. and Barrett, J.S. Population Pharmacokinetics of Fluconazole in Young Infants. Antimicrob. Agents Chemother., 2008, 4043-4049.
49. Piper, L.; Smith, P. B.; Hornik, C.P.; Cheifetz, I. M.; Barrett, J.S.; Moorthy, G.; Hope, W.W.; Wade, Ky C.; Cohen-Wolkowiez, M.; Benjamin, D.K. Jr. Fluconazole Loading Dose Pharmacokinetics and Safety in Infants. Pediatr. Infect. Dis. J., 2011 May, 30(5), 375-378.
50. Nahata, M.C.; Tallian, K.B.; Force, R.W. Pharmacokinetics of fluconazole in young infants. Eur. J. Drug Metab. Pharmacokinet., 1999 Apr-Jun, 24(2), 155-157.
51. Wenzl, T.G.; Schefels, J.; Hörnchen, H.; Skopnik H. Pharmacokinetics of oral fluconazole in premature infants. Eur J Pediatr., 1998 Aug, 157(8), 661-662.
52. Manzoni, P.; Stolfi, I.; Pugni, L.; Decembrino, L.; Magnani, C.; Vetrano, G., Tridapalli, E., Corona, G.; Giovannozzi, C.; M.D., Farina, D.; Arisio, R.; Merletti, F.; Maule, M.; Mosca, F.; Pedicino, R.; Stronati, M.; Mostert, M.; Gomirato, G.; A Multicenter, Randomized Trial of Prophylactic Fluconazole in Preterm Neonates. New England J.Med 2007; 356, 2483-2495
53. Kaufman, D.; Boyle, R.; Hazen, KC.; Patrie, JT.; Robinson, M.; Donowitz, L.G. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001 Dec 6; 345(23), 1660-6.
54. Wiest, D.B.; Fowler, S.L.; Garner, S.S.; Simons, D.R. Fluconazole in neonatal disseminated candidiasis. Archives in Diseases Childhood, 1991, 66, 1002.
55. Bergman, K.A., Meis, J.F., Horrevorts, A.M., Monnens, L. Acute renal failure in a neonate due to pelviureteric candidal bezoars successfully treated with long-term systemic fluconazole. Acta Paediatrica, 1992, 81 (9), 709-711.
56. Buchkowsky, S.; Patrtovi, N.; Ensom, M. Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther. Drug Monitor., 2005, 27, 322-333.
57. Abdel-Rahman, S.M.; Jacobs, R.F.; Massarella, J.; Kauffman, R.E.; Bradley, J.S.; Kimko, H.C.; Kearns, G.L.; Shalayda, K.; Curtin, C.; Maldonado, S.D. and Blumer, J.L. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-βcyclodextrin in infants, children and adolescents. Antimicrob. Agents Chemother., 2007, 51(8), 2668-2673.
58. Schmitt, C.; Perel, Y.; Harousseasu, J-L.; Lemerle, S.; Chwetzoff, E.;Le Moing, J-P.; Levron, J-C. Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis. Antimicrob. Agents Chemother., 2001, 45, 1561-1564.
59. De Repentigny, L.; Ratelle, J.; Leclerc, J.M., Cornu, G.; Sokal, E.M.; Jacqmin, P.; De Beule, K. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob. Agents Chemother., 1998 Feb, 42(2), 404-408.
60. Van der Anker, J.N.; Koster, M.; Woestenborghs, R.; Sauer, P.J.J. Itraconazole serum levels in the preterm neonate., Chemotherapy, 1992, 38 (suppl. 1), 58 abs.
61. Neely, M.; Rushing, T.; Kovacs, A.; Jelliffe, R.; Hoffman, J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis., 2010 Jan 1, 50(1), 27-36.
62. Walsh, T.J., Karlsson M.O., Driscoll, T. et al. Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration. Antimicrob. Agents Chemother., 2004, 48, 2166-2172.
63. Goldstein, J.A.; de Morais, S.M.F. Biochemestry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 1994, 4, 285-299.
64. Ikeda, Y.; Umemura, K.; Kondo, K.; Sekiguchi, K.; Miyoshi, S.; Nakashima, M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004;75, 587-8.
65. Wang, G.; Lei H.P.; Li, Z.; Tan, Z.R.; Guo, D.; Fan, L.; Chen, Y.; Hu, D.L.; Wang, D.; Zhou, H.H. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. European Journal of Clinical Pharmacology, 2009, 65 (3), 281-285
66. Desta, Z.; Zhao, X.; Shin, J.G.; Flockhart, D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin Pharmacokinet. 2002;41(12):913-58
67. Shima, H; Miharu, M; Osumi, T; Takahashi, T; Shimada, H. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer, 2010, 54, 1050-1052.
68. Frankenbusch K.; Eifinger F.; Kribs A.; Rengelshauseu J. and Roth. B., Severe pain cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight. Journal of Perinatology, 2006, 26, 511-514.
69. Cornely, O.A.; Maertens, J.; Winston, D.J. et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med., 2007, 356(4), 348-359.
70. Ullmann, A.J.; Lipton, J.H.; Vesole, D.H. et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med., 2007, 356(4), 335-347.
71. Brecht, M.; Clerihew, L. and McGuire. Prevention and tretament of invasive fungal infection in very low birth weight infants. Arch. Dis. Child. Fetal Neonatal Ed., 2009, 94, F65-F69.
72. Worth, L.J.; Blyth C.C.; Booth D.L.; Kong D.C.M.; Cassumbhoy M.; Ray J.; Slavin M.A. and Wilkes J.R. Optimal antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Internal Medicine Journal, 2008, 38, 521-537.
73. Sáez-Llorens, X.; Macias, M.; Maiya P.; Pineros, J.; Jafri, H.S.; Chatterjee, A.; Ruiz, G.; Raghavan, J.; Bradshaw, S.K.; Kartsonis N.A.; Sun P.; Strohmaier K.M.; Fallon M.; Bi S., Stone, J.A.; Chow, J.W. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother., 2009 Mar;53(3), 869-75.
74. Wiederhold, N.P. and Lewis, J.S. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Pharmacotherapy, 2007, 8 (8), 1155-1166
75. Hope, W.W.; Smith P.B.; Arrieta, A.; Buell D.N.; Roy M.; Kaibara, A; Walsh, T.J.; Cohen-Wolkowiez, M.; Benjamin, D.K. Jr. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother. 2010 Jun;54(6), 2633-7.
76. Hope, W.W.; Mickiene, D.; Petraitis, V.; Petraitiene, R.; Kelaher, A.M.; Hughes, J.E.; Cotton, M.P.; Bacher, J.; Keirns, J.J.; Buell, D.; Heresi, G.; Benjamin, D.K. Jr; Groll, A.H.; Drusano, G.L.; Walsh, T.J. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis. 2008 Jan 1;197(1), 163-71.
77. Heresi, G.P.; Gerstmann, D.R.; Reed, M.D.; van den Anker, J.N., Blumer, J.L.; Kovanda, L.; Keirns, J.J.; Buell, D.NN, Kearns, G.L. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006 Dec;25(12), 1110-5
78. Smith, P.B.; Walsh, T.J.; Hope, W.; Arrieta, A.; Takada, A.; Kovanda, L.L.; Kearns, G.L.; Kaufman, D.; Sawamoto, T.; Buell, D.N.; Benjamin, D.K.Jr. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J. 2009 May;28 (5), 412-5
79. Catalán-González, M.; Carlos Montejo-González, J. Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonates. Rev Iberoam Micol. 2009 Mar 31;26(1), 23-34. Epub 2009 May 7
80. Ramos Amador, J.T.; Prieto Tato, L.; Guillén Martín S. Why might micafungin be the drug of choice in pediatric patients? Enferm Infecc Microbiol Clin. 2011 Mar;29 Suppl 2, 23-8.
81. Benjamin, D.K. Jr.; Smith, P.B.; Arrieta, A.; Castro, L.; Sánchez, P.J.; Kaufman, D.; Arnold, L.J.; Kovanda, L.L.; Sawamoto, T.; Buell, D.N.; Hope, W.W.; Walsh, T.J. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2010 Jan;87(1), 93-9. Epub 2009 Nov 4
82. Kawada, M.; Fukuoka, N.; Kondo, M.; Okazaki, K.; Kusaka, T.; Kawada, K.; Itoh, S. Pharmacokinetics of prophylactic micafungin in very-low-birthweight infants. Pediatr Infect Dis J. 2009 Sep;28(9), 840-2
83. Lehrnbecher, T.; Groll A.H. Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients. Pediatr Blood Cancer. 2010 Aug; 55(2), 229-32
84. Dowell, J.A.; W. Knebel, T.; Ludden, M.; Stogniew, D.; Krause, and T. Henkel. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol. 2004, 44, 590-598
85. Cohen-Wolkowiez, M.; Benjamin, D.K. Jr.; Piper, L.; Cheifetz, I.M.; Moran, C.; Liu, P.; Aram, J.; Kashuba, A.D.; Capparelli, E.; Walsh, T.J.; Hope, W.W.; Smith, P.B.Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmacol Ther. 2011 May; 89(5), 702-7. Epub 2011 Mar
86. Manolis, E.; Pons, G. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. Br J Clin Pharmacol. 2009 Oct;68[4], 493-501
87. EMEA. EMEA Workshop on Modelling in Paediatric Medicines. London: EMEA; pp. 14-15. April 2008 http://www.emea.europa.eu/htms/human/paediatrics/workshops.htm
88. Katragkou, A.; Roilides, E. Best practice in treating infants and children with proven, probable or suspected invasive fungal infections Curr Opin Infect Dis. 2011 Jun;24(3), 225-9.
89. Gallagher, J.C. Clinical Application of Antifungal Pharmacodynamics, Current Fungal Infection Reports, 2009, 3, 69-76
90. Smith, J. and Andes, D. Therapeutic drug monitoring and pharmacodynamic considerations. Ther. Drug Monit. 2008, 30(2), 167-172
91. Goodwin, M. and Drew, R.H. Antifungal serum concentration monitoring: an update. Journal of Antimicrobial Chemotherapy. 2008, 61, 17-25
92. Ashley, E.S.D.; Lewis, R.; Lewis, J.S.; Martin, C.; Andes, D. Pharmacology of systemic antifungal agents. CID 2006, 43, S28-S39
93. Billaud, E.M.; Romain, G.; Berge, M; Amrein, C.; ,SANDRINE Lefeuvre, S; Lillo-Le Louet, A.; Boussad, V.; Chevalier, P. Pharmacological considerations for azole antifungal drug management in cystic fi brosis lung transplant patients. Medical Mycology 2010, 48 [Suppl. 1], S52-S59.